Health News Archive - May 30, 2010
BERLIN, May 30 /PRNewswire/ -- Celladon Corp., a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, today announced that six-month data from its Phase 2 clinical trial of MYDICARÂ® show improvements in clinical outcomes and disease markers in advanced heart failure patients treated with the genetically targeted enzyme replacement therapy.
- Stoppage; cessation (of labor).
- A standing still or idling (of mills, factories, etc.).